# Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

Study · id `cardio:ct-nct07430956` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07430956](<https://clinicaltrials.gov/study/NCT07430956>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07430956

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2628 participants.

## Technical summary

Registry record NCT07430956. Randomized; quadruple masking; primary purpose prevention. Start 2026-04-03 (actual); primary completion 2029-03-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 2628 participants (planned count; ClinicalTrials.gov record NCT07430956, source copy `cardio:ctgov-nct07430956-2026-11-17`, retrieved 2026-11-18)
- Started: 2026-04-03 (actual) (ClinicalTrials.gov record NCT07430956, source copy `cardio:ctgov-nct07430956-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2029-03-28 (anticipated) (ClinicalTrials.gov record NCT07430956, source copy `cardio:ctgov-nct07430956-2026-11-17`, retrieved 2026-11-18)
- Completion: 2029-06-26 (anticipated) (ClinicalTrials.gov record NCT07430956, source copy `cardio:ctgov-nct07430956-2026-11-17`, retrieved 2026-11-18)
- Countries: United States; Canada (ClinicalTrials.gov record NCT07430956, source copy `cardio:ctgov-nct07430956-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07430956-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
- Acronym: ROXI-INCLINE
- Condition: Atrial Fibrillation (AF)
- Intervention (Drug): REGN7508
- Intervention (Drug): REGN9933
- Intervention (Drug): Placebo
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: b07965521e743ecb85713eb566ab5ae68b16e0184e12b0eb30c712a36cd049ee
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
